baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BVT Call 260 BIIB 20.12.2024/ DE000VM7SCM6 /

9/13/2024 8:24:04 AM	Chg.-0.029	Bid1:09:01 PM	Ask1:09:01 PM	Underlying	Strike price	Expiration date	Option type
0.098EUR	-22.83%	0.101 Bid Size: 18,000	0.119 Ask Size: 18,000	Biogen Inc	260.00 USD	12/20/2024	Call

GlobeNewswire 9/1 SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Invest...

GlobeNewswire 8/29 SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investo...

GlobeNewswire 8/26 Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encoura...

GlobeNewswire 8/26 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...

GlobeNewswire 8/22 Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...

GlobeNewswire 8/19 Tiziana Life Sciences Appoints New Chief Executive Officer

GlobeNewswire 8/19 Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief ...

GlobeNewswire 8/15 Soleno Therapeutics Announces Updates to its Board of Directors

GlobeNewswire 8/15 Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...

GlobeNewswire 8/8 Royalty Pharma Reports Second Quarter 2024 Results

GlobeNewswire 8/1 C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

TeleTrader 8/1 Biogen books $2.5 billion in Q2 revenue

GlobeNewswire 8/1 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 7/31 Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

GlobeNewswire 7/30 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...

GlobeNewswire 7/30 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...

GlobeNewswire 7/30 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...

GlobeNewswire 7/26 CVS Health Corporation Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law...

GlobeNewswire 7/26 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

GlobeNewswire 7/26 BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockh...

GlobeNewswire 7/22 Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Fir...

GlobeNewswire 7/22 DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of...

GlobeNewswire 7/20 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen...

GlobeNewswire 7/20 BIIB DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Biogen Inc. (BIIB) Se...

GlobeNewswire 7/19 MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors wit...

BVT Call 260 BIIB 20.12.2024/ DE000VM7SCM6 /

If you wish to receive reply to your feedback, please provide your email address.